A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Latest Information Update: 28 Jun 2023
Price :
$35 *
At a glance
- Drugs CGX 1321 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Curegenix
- 06 Jun 2023 Results ( As of January 1, 2023), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 22 Jul 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 22 Jul 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.